Pilot Study of RR-HNK in OCD ((HNKO))

This double-blind, placebo-controlled trial (n=45) will study the safety and efficacy of two dosage levels of intravenous (2R,6R)-Hydroxynorketamine (RR-HNK) in adults with obsessive-compulsive disorder (OCD).

The study, conducted by researchers likely affiliated with Stanford University (based on the contact information), aims to understand how RR-HNK works in the brain to reduce OCD symptoms. Participants aged 18-65 with OCD who have failed at least one prior standard treatment will be randomised into three groups: 0.25 mg/kg RR-HNK, 0.5 mg/kg RR-HNK, or placebo (sterile saline).

Each group will receive a single infusion, with EEG and computerised behavioural tests conducted before and after the infusion. The primary outcome measure will be the change in OCD symptom severity as measured by the Yale-Brown Obsessive Compulsive Scale (YBOCS) from baseline to one week post-infusion. This phase 1/2 trial is expected to run from December 2024 to November 2029, potentially offering new insights into novel treatments for OCD using ketamine metabolites.

Topic Obsessive-Compulsive Disorder
Compound Ketamine
Country United States of America
Visit trial
Status Not yet recruiting
Results Published No
Start date 01 December 2024
End date 30 November 2028
Phase Phase I Phase II
Design Blinded
Type Interventional
Generation Second
Participants 45
Sex All
Age 18- 65
Therapy No

Trial Details

This protocol examines the safety and efficacy of 2 dosage levels of intravenous RR-HNK administration in individuals with OCD.

NCT Number NCT06575075

Sponsors & Collaborators

Stanford University
Researchers at Stanford are exploring the potential of ketamine, MDMA and psilocybin by connecting neuroscience, psychiatry and anesthesiology.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.